AG真人官方

Form 144 filing for Silicon Laboratories, Inc. (SLAB) documents a proposed sale of 1,800 common shares through Fidelity Brokerage Services on 08/29/2025 with an aggregate market value of $240,426.18. The filing states the shares were acquired via an option granted 01/28/2016 and payment is by cash. The issuer's reported number of shares outstanding is 32,815,310. The filer, identified by name in past sales, sold 2,270 shares on 08/19/2025 for $301,206.53 and 8,000 shares on 08/22/2025 for $1,161,817.60. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.

Silicon Laboratories Inc. director and Senior Vice President WW Sales & Marketing Brandon Tolany reported transactions on 08/22/2025 involving 8,000 common shares acquired and 8,000 common shares sold. Tolany exercised 8,000 non-qualified stock options with an exercise price of $43.82 per share and acquired 8,000 shares. Those same 8,000 shares were sold the same day at a weighted average price of $145.23, with individual sale prices ranging between $145.13 and $145.36. Following these transactions, Tolany鈥檚 reported beneficial ownership decreased from 70,328 shares to 62,328 shares. The Form 4 is a single-person filing and includes a handwritten signature date of 08/22/2025 by Saie-Yau Hui for Brandon Tolany.

Form 144 notice by an insider proposing sale of Silicon Laboratories Inc. common stock. The filer plans to sell 8,000 shares through Fidelity Brokerage Services with an aggregate market value of $1,161,818.01 on or about 08/22/2025. The shares were acquired via an option granted on 01/28/2016 and payment on sale is listed as cash. The issuer's outstanding shares are reported as 32,815,310. A recent sale by Brandon Tolany of 2,270 shares on 08/19/2025 generated $301,206.53. The filer certifies no undisclosed material adverse information.

Tolany Brandon, Sr VP WW Sales & Marketing at Silicon Laboratories Inc. (SLAB), reported transactions on 08/19/2025 involving exercises of stock options and an open-market sale. The filing shows exercises of two non-qualified stock options at an exercise price of $43.82 each, resulting in the acquisition of 35 and 2,235 shares. The filing also reports a sale of 2,270 shares at $132.69. After these transactions, the reported beneficial ownership totals are shown as 62,328 shares (final reported balance). The option grants cited have original grant dates of 01/28/2019 and 01/28/2020 with expiration 01/28/2026.

The filing is a Form 144 notice from an individual related to Silicon Laboratories Inc. It reports a proposed sale of 2,270 shares of Common stock through Fidelity Brokerage Services on the NASDAQ, with an aggregate market value of $301,206.53 and 32,815,310 shares outstanding for the class. The shares were acquired via an option granted on 01/28/2016 and are indicated as acquired on 08/19/2025; payment is listed as cash. The filer reports no other sales in the past three months and includes the standard representation that they are not aware of undisclosed material adverse information about the issuer.

Capital Research Global Investors disclosed beneficial ownership of 1,206,937 shares of Silicon Laboratories Inc. common stock, equal to 3.7% of the 32,571,850 shares the filer believes are outstanding. The filing identifies CRGI as a division of Capital Research and Management Company and states that the investment management entities acting under the CRGI name are deemed the beneficial owner of these shares.

The statement indicates CRGI has sole voting and sole dispositive power over the reported shares and certifies the securities were acquired and are held in the ordinary course of business, not to change or influence control of the issuer.